


## Properties

<b>Description</b>	Recombinant bivalent Nanobody against the Receptor-binding domain (RBD) of SARS-CoV-2 Spike protein
<b>Species Specificity</b>	Virus
<b>Source</b>	Alpaca, recombinantly produced
<b>Class</b>	Recombinant
<b>Type</b>	Nanobody / VHH, biparatopic
<b>Clonality</b>	Monoclonal
<b>Clone No.</b>	NM1267 (NM1230-NM1226 fusion) [Wagner et al. EMBO Rep. 2021 May 5;22(5):e52325. PMID: 33904225]
<b>RRID</b>	AB_2892257
<b>Epitope</b>	NM1230: Amino acids 351 and 437-503 (determined by X-Ray crystallography) NM1226: Amino acids 369-384 and 405, 408 and 504-508 (determined by HDX-MS)
<b>Immunogen</b>	RBD of SARS-CoV-2 Spike protein
<b>Full Name</b>	SARS-CoV-2 Spike protein
<b>Calculated MW</b>	25 kDa
<b>GenBank Accession Number</b>	NC_045512
<b>Gene Symbol</b>	COVID-19 S Protein
<b>GeneID (NCBI)</b>	43740568
<b>Affinity (<math>K_D</math>)</b>	NM1230: 9.5 nM NM1226: 7.0 nM
<b>Conjugate</b>	Unconjugated
<b>Form</b>	Liquid
<b>Purification Method</b>	Recombinant expression, affinity purification by IMAC. <i>Note: SARS-CoV-2 Spike Recombinant VHH carries a C-terminal His-tag.</i>
<b>Concentration</b>	1000 µg/mL (34.9 µM)
<b>Tested Applications</b>	Bio-Layer Interferometry (BLI)
<b>Positive Controls</b>	BLI: biotinylated RBD and SARS-CoV-2 Spike Recombinant VHH
<b>Cited Applications</b>	BLI, Multiplex ACE2 competition assay <i>Note: Not recommended for Western blotting.</i>

Reference	Wagner et al. EMBO Rep. 2021 May 5;22(5):e52325. PMID: 33904225
Cited Assay Concentration	Multiplex ACE2 competition assay: 8 pM - 126 nM
Storage Buffer	PBS, 0.09% sodium azide Safety datasheet (SDS): sodium azide
Storage Conditions	Aliquot upon receipt and store at -20°C/-4°F. Avoid freeze-thaw cycles.
Stability	Stable for 1 year at -20°C/-4°F after shipment.
Shipment	Shipped at ambient temperature
Size	20 µg; 100 µg

## Selected validation data



*BLI binding kinetics of SARS-CoV-2 Spike Recombinant VHH [NM1267] to RBD. Biotinylated RBD was immobilized on FortéBio Streptavidin (SA) Biosensors and assayed with 25 nM of SARS-CoV-2 Spike Recombinant VHH [NM1267] (ChromoTek sc-NM1267). For comparison the binding kinetics of 25 nM SARS-CoV-2 Spike Recombinant VHH [NM1226] (ChromoTek sc-NM1226) and SARS-CoV-2 Spike Recombinant VHH [NM1230] (ChromoTek sc-NM1230) are shown.*

## Product overview and related products

SARS-CoV-2 Spike Recombinant VHHs	Product code
SARS-CoV-2 Spike Recombinant VHH [NM1220]	sc-NM1220-20; -100
SARS-CoV-2 Spike Recombinant VHH [NM1221]	sc-NM1221-20; -100
SARS-CoV-2 Spike Recombinant VHH [NM1222]	sc-NM1222-20; -100
SARS-CoV-2 Spike Recombinant VHH [NM1223]	sc-NM1223-20; -100
SARS-CoV-2 Spike Recombinant VHH [NM1224]	sc-NM1224-20; -100
SARS-CoV-2 Spike Recombinant VHH [NM1226]	sc-NM1226-20; -100
SARS-CoV-2 Spike Recombinant VHH [NM1227]	sc-NM1227-20; -100
SARS-CoV-2 Spike Recombinant VHH [NM1228]	sc-NM1228-20; -100
SARS-CoV-2 Spike Recombinant VHH [NM1229]	sc-NM1229-20; -100
SARS-CoV-2 Spike Recombinant VHH [NM1230]	sc-NM1230-20; -100
SARS-CoV-2 Spike Recombinant VHH [NM1266]	sc-NM1266-20; -100
SARS-CoV-2 Spike Recombinant VHH [NM1267]	sc-NM1267-20; -100

For product details, information, and ordering visit <https://www.ptglab.com/>.

## Contact

support@chromotek.com

ChromoTek GmbH  
Am Klopferspitz 19  
82152 Planegg-Martinsried  
Germany  
phone: +49 89 124 148 80  
fax: +49 89 124 148 811

ChromoTek Inc.  
62-64 Enter Lane  
Islandia, NY 11749  
USA  
phone: 631 501 1058  
fax: 631 501 1060

## Disclaimer

Only for research applications, not for diagnostic or therapeutic use!

ChromoTek is a registered trademark of ChromoTek GmbH, part of Proteintech Group. Nanobody is a registered trademark of Ablynx, a Sanofi company. Other suppliers' products may be trademarks or registered trademarks of the corresponding supplier each. Statements on other suppliers' products are given according to our best knowledge.